1 Improved biorepository to support sickle cell disease genomics and clinical

2 research: A practical approach to link patient data and biospecimens from

3 Muhimbili Sickle Cell Program, Tanzania

- 4 Upendo Masamu^{1*}, Raphael Z Sangeda^{1,2}, Josephine Mgaya¹, Siana Nkya³, Beatrice Octavian¹,
- 5 Frank R Mtiiye¹, Joyce Nduguru¹, Agnes Jonathan¹, Daniel Kandonga¹, Irene K Minja^{1,4},
- 6 Paschal Rugajo^{1,5}, Emmanuel Balandya⁶, Julie Makani^{1,7}
- 7 ¹Muhimbili Sickle Cell Program, Department of Hematology and Blood Transfusion,
- 8 Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- 9 ²Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied
- 10 Sciences, Dar es Salaam, Tanzania.
- ³Department Biochemistry, Muhimbili University of Health and Allied Sciences, Dar es
 Salaam, Tanzania.
- ⁴Department of Restorative Dentistry, Muhimbili University of Health and Allied Sciences,
- 14 Dar es Salaam, Tanzania.
- ⁵Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar
 es Salaam, Tanzania.
- ⁶Department of Physiology, Muhimbili University of Health and Allied Sciences, Dar es
 Salaam, Tanzania.
- ⁷Department of Hematology and Blood Transfusion, Muhimbili University of Health and
 Allied Sciences, Dar es Salaam, Tanzania.
- 21
- 22 * Corresponding author: umasamu@blood.ac.tz

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

24 Genetic modifiers underlying various sickle cell disease phenotypic expressions are largely 25 unexplored in Africa due to lack of databases linking biospecimens with demographic and 26 clinical data. The problem may be compounded by a complete lack of biorepositories in these 27 settings. This article aims to document the physical verification of biospecimens stored in the 28 biorepository and link them to patient clinical and demographic information to facilitate plans 29 for genomic and related clinical research studies. We reviewed and updated the existing 30 biorepository infrastructure at Muhimbili Sickle Cell Programme in Dar es Salaam, Tanzania. 31 The database of archived biospecimens was updated with the location information of respective biospecimens following the physical verification of biospecimens and then mapping the patient 32 33 demographic and clinical data with the biospecimen data using sickle cell patients' 34 demographic identifiers. Three freezers maintained at -80°C store a total of 74,079 35 biospecimens, of which 63,345 were from 5,159 patients registered in the Muhimbili Sickle Cohort from 2004 to 2016. Out of stored biospecimens, follow-ups were 46,915 (74.06%), 36 37 control 8,067 (12.74%), admission 5,517 (8.71%) and entry 2,846 (4.49%). Of these registered 38 patients, females were 2,521 (48.87%) and males were 2,638 (51.13%). The age distribution 39 was 1 to 59 years, with those above 18 years being 577 (11.18%) and children 4,582 (88.82%) 40 of registered patients. The notable findings during the process include a lack of automated 41 biospecimen checks, laboratory information management system and standardization of 42 equipment used, biospecimens not linked to clinical and demographic data, date format 43 inconsistencies, lack of regular updating of a database on exhausted biospecimens and updates 44 when biospecimens are moved between positions within freezers. Well-organized 45 biorepository plays a crucial role in answering future research questions. Enforcing strict 46 standard operating procedures and quality control standards will ensure that laboratory scientists and other users adhere to the best biospecimen management procedures. 47

49 Introduction

50 Sickle cell disease (SCD) is an inherited disease caused by a single-gene mutation affecting the 51 β-globin gene on chromosome 11. It results in an abnormal hemoglobin protein (HbS) which 52 affects the shape and function of red blood cells (RBC) and subsequently impacts nearly all 53 body organ systems [1,2]. SCD is one of the most prevalent inherited blood disorders. An 54 estimated 300,000 individuals are born each year with SCD, the highest burden being in Africa, 55 where up to 75% of SCD births occur [3]. It is estimated that 50–80% of infants born with SCD 56 in Africa die before the age of 5 years [4]. Research on SCD is crucial, allowing the discovery 57 of a cure that will reduce its burden on afflicted families. Therefore, it is imperative that the 58 current and future research on SCD store and maintain biospecimens appropriately linked to 59 their clinical and demographic information.

60 Biorepositories hold a crucial role in achieving biomedical progress and improving research 61 capacity in Africa [5–7], given the advancements in technology in medical sciences. 62 Biospecimens should be stored in a manner to support not only current use but also future clinical or research studies. Human biorepositories are used to understand diseases and 63 64 diagnoses and ultimately provide information on the cure and treatment [8,9]. Several 65 initiatives have been established to support African biorepository activities. Such initiatives 66 include the Human, Heredity, and Health in Africa (H3Africa), which has helped several 67 biorepositories such as the Integrated Biorepository at Makerere University College of Health Sciences (IBRH3AU), Institute of Human Virology (IHV) H3Africa Biorepository in Abuja 68 Nigeria Clinical Laboratory Services (a Division of the Wits Health Consortium) in 69 70 Johannesburg South Africa. According to the literature, Gambia was the first country in Africa 71 to establish a national DNA bank [10,11]. Sustainability and the ability to answer research questions are critical for a standard biorepository [12–15]. A well-maintained biorepository is 72 73 expected to have stored biospecimens to ensure quick biospecimen retrieval and the validity of

74 the analytical tests. This includes a clear link between the biospecimen data and clinical and 75 demographic information, increasing the scientific value of stored biospecimens [16,17]. This 76 can be achieved if clearly defined procedures govern biorepository processes. Several 77 discussions have been around regarding the standards that any biorepository is supposed to 78 have. One of the discussions is on standard operating procedures (SOPs) for biorepository 79 processes such as sample collection, storage, processing, and information management such as Laboratory information management system (LIMS) [16,18,19]. There are few established 80 81 biorepositories for SCD globally. These establishments would speed the discovery of 82 mitigations against SCD, including discovering novel biological markers for treatment.

83 The Muhimbili Sickle Cell Programme at the Muhimbili University of Health and Allied 84 Sciences (MUHAS) in Tanzania was established in 2004 and aimed to offer clinical care and 85 build research capacity in SCD [1,3]. The program recruited a Muhimbili Sickle Cell Cohort 86 (MSC) database of over 5,000 SS individuals, including their demographic, clinical, and 87 biospecimens data. The main goal of the program was to conduct research on SCD that will 88 identify the disease spectrum, causes of disease morbidity and mortality, and describe genetic 89 determinants of the disease [20–25]. Following the research impact achieved with the MSC[3], 90 MUHAS was awarded twice a grant named Sickle Pan African Consortium (SPARCo) by the 91 National Institutes of Health (NIH). This was a collaborative grant between MUHAS in 92 Tanzania as a research hub and a site, Cape Town University as a data coordinating center and 93 two other research sites in Nigeria and Ghana in phase 1 between 2017 and 2021. In phase 2, granted between 2021 and 2026, additional three sites in four countries (Mali, Uganda and a 94 95 shared site in Zimbabwe and Zambia) were established. SPARCo plans to conduct genomic 96 and clinical studies in the second phase of the SPARCo grant award [26].

97 The challenge in Muhimbili Sickle Program and other centers in African counties is the ability98 to manage and trace biospecimens that move between different positions and locations in the

99 biorepository. In addition, linking the biospecimen data to the clinical and demographic data is 100 tedious without an automated way of handling and storing biospecimens. Linking the 101 biospecimens with their clinical and demographic data is essential because it may give insight 102 into the pattern that may accelerate SCD research progress and discovery. Furthermore, 103 automatic handling and storing of biospecimens is necessary to allow biospecimen integrity 104 and reproducibility of results [19,27]. To achieve this goal, this study was designed to facilitate 105 genomics research by preparing easily maintainable records of biospecimens from the previous 106 MSC cohort and new biospecimens from patients. We describe the experience of conducting 107 quality control and verifying all archived biospecimens from Muhimbili Sickle Program and 108 Sickle Pan African Research Consortium (SPARCo) and integrate the biospecimen database 109 with the clinical and demographic data using the Research Electronic Data Capture (REDCap). 110 The system established will allow quick and intuitive data management that is scalable. The 111 documentation of quality assured biorepository shall serve as the basis for other SSA countries 112 to emulate in practice and pave the way for collaborative genomic studies utilizing the existing 113 biospecimens.

114

115 MATERIALS AND METHODS

116 Study design and population

The study was conducted among patients who consented to participate in the MSC study and its nested studies, such as the Vascular Function Intervention Trial (VFIT) and Strategic Award Study [3,28]. The enrollment into the MSC included all individuals who attended a clinic or patients suspected clinically diagnosed to have SCD at Muhimbili National Hospital (MNH) in Dar es Salaam, Tanzania. Patients were registered mainly from the coastal regions and other regions in Tanzania.

123 Ethics Statement

The Senate Research and Publications Committee of the Muhimbili University of Health and
Allied Sciences (MUHAS) in Tanzania approved the study (Ref. No.DA.282/298/01.C/).
Written informed consent was obtained from all participants. For individuals 18 years or above,
while for minors, a parent/ guardian consented and signed the consent on behalf of the patient;
adolescents provided assent.

129 **Biospecimens verification**

130 The study reviewed, quality assured and updated the existing biorepository infrastructure at the 131 program to link SCD biospecimen data with their clinical and demographic data. During the MSC, patients were identified at entry, admission, follow-up, and as a control which were 132 133 recorded as visit types. Different biospecimens were collected, including plasma, buffy coat, serum, DNA and isolates. These biospecimens were stored in microtubes within a cryobox, 134 135 whereby one cryobox would only store one biospecimen type for a specific study. The 136 cryoboxes were labeled on top with the study name, biospecimen type and box number. The numbers on the cryobox were unique for each biospecimen type throughout the study. Basic 137 138 clinical and demographic information was collected using case report forms (CRF).

Physical verification of biospecimen location within a freezer was done by verifying information such as freezer number, a compartment within a freezer, rack and box number. Information regarding the biospecimen, such as type and study, were also verified during the process. Data from physical verification were compared to the one on the database and updated corresponding records. The final database was cleaned up by maintaining all records of biospecimens found in the freezers during physical verification and having all the verified information about the biospecimens and freezer locations.

146

Tubes found empty and still in the freezers were removed and updated in the database. The 147 148 clean biospecimen data was mapped and linked to its clinical and demographic information 149 using demographic identifiers through which two categories were identified cohort-related for 150 whom demographic identifiers were available and non-cohort for biospecimens from patients 151 not admitted in the MSC cohort. The clean final biospecimen data were migrated to the 152 REDCap database to allow easy record-keeping and retrieval. A REDCap (Research Electronic 153 Data Capture) database was created to store curated biospecimens and patient data from this 154 study. REDCap is a secure, web-based application designed to support data capture for research 155 studies, providing (1) an intuitive interface for validated data entry; (2) audit trails for tracking 156 data manipulation and export procedures; (3) automated export procedures for seamless data 157 downloads to standard statistical packages; and (4) procedures for importing data from external 158 sources [29,30]. The REDCap system and tools were hosted at Muhimbili University of Health 159 and Allied Science.

160

161 Data analysis plan

Descriptive such as counts, averages and proportions were used to summarize patients'
demographic and biospecimen data. Rstudio 2022.07.2 was used for summarizing the data.

164 **Results**

The Hematology Clinical and Research Laboratory (HCRL) at Muhimbili has three freezers (Fig1A) used to store the biospecimens from MSC. The freezer has three areas within a compartment, columns, and rows (Fig1B). Biospecimens of types of plasma, buffy coat, deoxyribonucleic acid (DNA), serum, urine, washed red blood cells and bacterial isolates were aliquoted in the 0.5-2uL microtubes and arranged in 9x9 cryoboxes. The freezers were monitored for temperature checks twice daily and adequately documented. A backup generator

171 is connected to the main power of the laboratory to observe the quality of the archived biospecimens in case of a power failure. Currently, the HCRL contains a total of 74,079 172 173 biospecimens. The space occupied by these biospecimens was 70% of the available space for 174 archived biospecimens stored in the three -80°C freezers.

175

176 Out of 74,079 archived biospecimens, 63,345 biospecimens were from 5,159 patients registered under MSC. The remaining 10,734 biospecimens were from nested studies within 177 178 the MSC. More patients were seen at the inception of the project in 2004, but in 2016 new 179 clinics were opened at other referral hospitals that patients were referred to instead of coming to Muhimbili (Fig 2). Of 5,159 registered patients, the females were 2,521 (48.87%), while the 180 181 males were 2,638 (51.13%). In terms of age distribution, the minimum age was less than one 182 year while the maximum age was 59, with those above 18 years being 577 (11.18%), while 183 children were 4,582 (88.82%) of registered patients under MSC "Table 1". The total number 184 of biospecimens collected per patient is categorized in Fig 3. The group labeled 1 is the group with patients with only one biospecimen collected and others are in intervals of 10 185 186 biospecimens.

Attribute	N (%)	Test statistics		
		(p-value)		
Gender				
Female	2,521 (48.87%)			
Male	2,638 (51.13%)	$\chi^2 = 2.65(0.1033)$		
Age (years)		··· · · ·		
Minimum	< 1 year			
Maximum	59			
Average	8.29			
Age category (N (%))				
Adults	577 (11.18%)			
Children	4,582 (88.82%)	$\chi^2 = 3109.10 (< 0.001)$		

188	Table 1: Demographic	characteristics of patients	under the Muhimbili Sickle Cohort
	Attribute	N (%)	Test statistics

189

190	Out of 63,345 biospecimens that were collected per each visit type follow-ups were 46,915
191	(74.06%), control 8,067 (12.74%), admission 5,517 (8.71%) and entry 2,846 (4.49%) "Table
192	2". From the physical verification, biospecimen types present include plasma 38,008 (60.00%),
193	buffy coat 15,323 (24.19%), serum 4,671 (7.37%), DNA 4,528 (7.15%) and bacterial isolates
194	258 (0.41%) "Table 3". The 557 biospecimens "Table 3" were from a nested study on Amino
195	Acids in Tanzanian Children with Sickle Cell Disease under Vascular Function Intervention
196	Trial (V-FIT)[31]. One of the outcomes of the verification process was to generate and update
197	freezer plan maps, usually placed in front of the freezer showing the position of boxes with
198	biospecimens within the freezers. The map captures the biospecimen type, box number,
199	compartment, rack position within a freezer and the visit type (Fig 1C).

200 **Table 2:** Number of archived biospecimens per year and visit type under Muhimbili Sickle

201 Cohort

Year	Admission	Control	Entry	Follow-up	Year total
2004	34	10	965	1,144	2,153 (3.40%)
2005	442	154	255	4,261	5,112 (8.07%)
2006	224	275	381	4,785	5,665 (8.94%)
2007	359	859	336	7,575	9,129 (14.41%)
2008	619	1,221	266	6,270	8,376 (13.22%)
2009	564	423	80	4,409	5,476 (8.64%)
2010	529	462	63	3,847	4,901 (7.74%)
2011	857	1,025	106	5,258	7,246 (11.44%)
2012	607	696	139	3,162	4,604 (7.27%)
2013	568	1,032	154	3,255	5,009 (7.91%)
2014	391	1,232	78	2,393	4,094 (6.46%)
2015	323	637	23	524	1,507 (2.38%)
2016		41		32	73 (0.12%)
Visit type total	5,517 (8.71%)	8,067 (12.74%)	2,846 (4.49%)	46,915 (74.06%)	63,345

Table 3: Number of each archived biospecimen type under the Muhimbili Sickle Cohort

Year	Buffy coat	DNA	Isolates	Plasma	Serum	V-FIT
2004	589	20		1,153	391	
2005	2,407	93		2,420	192	

Discussion						
type total	(24.19%)	(7.15%)	(0.41%)	(60.00%)	(7.37%)	(0.88%)
Biospecimen	15,323	4,528	258	38,008	4,671	557
2016	52			21		
2015	550			816	141	
2014	1,604			2,267	140	83
2013	1,993			2,487	223	306
2012	1,624			2,559	253	168
2011	1,339	1,172		4,365	370	
2010	254	296	3	4,139	209	
2009	603	205	54	3,857	757	
2008	738	673	95	6,292	578	
2007	1,449	1,829	37	4,699	1,115	
2006	2,121	240	69	2,933	302	

204

205 This paper documents best practices and challenges from verifying archived biospecimens and 206 experience at the Muhimbili Sickle Cell Program in Dar es Salaam, Tanzania. Physical 207 verification of archived biospecimens was carried out whereby a total of 74,079 biospecimens 208 were archived, of which 63,345 biospecimens were from 5,159 patients registered under MSC. 209 Different biospecimens, such as buffy coat, plasma, DNA, serum and bacterial isolates, were 210 archived.

211 During the physical verification process, some observations needed to be addressed to have a 212 sustainable biorepository to answer future research questions. The absence of an automated 213 way of handling biospecimens made the verification process tedious and manual. The lack of 214 automatic biospecimen checks added to the long, tedious biospecimen verification process. 215 Institutions planning to have biorepositories should consider having an automated way of 216 handling biospecimens, such as a Laboratory Management Information System (LIMS), to 217 allow automatic biospecimen checks that will enable fast and efficient tracking of archived 218 biospecimens. The use of an automated way of handling and storing biospecimens was also 219 recommended by other researchers to preserve biospecimen integrity and allow the 220 reproducibility of results [19,27,32,33].

221 Some of the tubes with archived biospecimens were missing date labels that indicate when the 222 biospecimens were taken. The recording of the date on the tube needs to be enforced because 223 biospecimens are only kept for a specific period and those with no dates may need to be 224 discarded. Proper date annotation is critical to allow biospecimens' data integrity and quality 225 [17,19]. In addition, some of the archived biospecimens were exhausted in the freezer, but their 226 information was not updated in the database. This calls for laboratory scientists to regularly 227 update the database with information on the exhausted biospecimens. This will allow other 228 users to be informed of the finished biospecimens. The process can be enforced and make laboratory scientists more accountable by implementing a LIMS that tracks users' activities by 229 230 their identifiers [32].

Lack of standards on the type of tube to be used, whereby some tubes had volume labels while some did not. The absence of a volume label caused difficulties verifying the volume for the archived biospecimens. This calls for developing an SOP on the standard of the types of equipment to be used for biospecimen archiving, which will guide the procurement of respective equipment. Other researchers also recommended the need to have SOPs for the procurement of biospecimen archiving equipment [8].

237 Different recorded date formats from multiple users who entered data in Microsoft Excel. The date format challenge can also occur when a proper database system is in place. However, the 238 239 database management engine usually handles date format issues more conveniently. Internet 240 connectivity is another challenge in Africa, preventing real-time access to LIMS. In such cases, 241 laboratory scientists may use MS Excel to temporarily log data and then later import it to an 242 internet database via LIMS. Hence to overcome these challenges, there is a need to have an SOP in place that map the process of recording information for the biospecimen [8]. Such SOP 243 244 includes a clause defining a date format to be used and adhered to.

245 It was also observed that some biospecimens were moved to new positions within a freezer, 246 but that information was not updated in the biospecimens' database. This calls for logging to 247 track biospecimens' movement within the freezer to account for biospecimen misplacement. 248 Furthermore, a few tubes were empty and still found in the freezer. Strict rules and SOP should 249 be implemented to guide laboratory scientists on biospecimen management. Such rules include 250 removing empty tubes once exhausted and updating the database. In addition, there should be 251 ownership of the biospecimen management systems among the users. This means a person who 252 oversees and enforces all the rules should be answerable to all queries [34]. Staff training and 253 periodic review of processes are essential to ensure that SOPs are being adhered to [33,34].

254 Conclusion

255 The biorepository plays a crucial role in answering future research questions to allow the discovery of novel genomic markers for diagnosing and treating SCD. However, this will be 256 257 achieved if biospecimens are adequately managed. Strict controlled standard operating 258 procedures and quality assured and quality controlled standards must be enforced to ensure that 259 laboratory scientists and other users adhere to the best biospecimen management procedures. 260 This includes SOP for the procurement of standard equipment, biospecimen storage (such as 261 biospecimen labeling during archiving), and movement from and to the freezers. Regular training on best practices and SOPs for new staff and refresher training for existing ones. 262 263 Furthermore, one should have LIMS and automatic checks that will allow fast and efficient tracking of archived biospecimens. 264

265

266 Acknowledgments

We would like to thank SCD patients whose data were used in this study and all staff at theMuhimbili Sickle Cell Program for their support.

269 Author Contributions

- 270 **Conceptualization:** Raphael Z Sangeda
- 271 Investigation: Upendo Masamu, Josephine Mgaya, Beatrice Octavian and Frank R Mtiiye
- 272 Formal analysis and Visualization: Upendo Masamu and Raphael Z Sangeda
- 273 Writing Original Draft Preparation: Upendo Masamu, Raphael Z Sangeda, Josephine
- 274 Mgaya, Siana Nkya, Beatrice Octavian, Frank R Mtiiye, Joyce Nduguru, Agnes Jonathan,
- 275 Daniel Kandonga, Irene K Minja, Paschal Rugajo, Emmanuel Balandya and Julie Makani
- 276 Writing Review & Editing: Upendo Masamu, Raphael Z Sangeda, Josephine Mgaya, Siana
- 277 Nkya, Beatrice Octavian, Frank R Mtiiye, Joyce Nduguru, Agnes Jonathan, Daniel Kandonga,
- 278 Irene K Minja, Paschal Rugajo, Emmanuel Balandya and Julie Makani.
- 279

280 References

- Tluway F, Makani J. Sickle cell disease in Africa: an overview of the integrated
 approach to health, research, education and advocacy in Tanzania, 2004-2016. Br J
 Haematol. 2017 Jun;177(6):919–29.
- Masamu U, Sangeda RZ, Kandonga D, Ondengo J, Ndobho F, Mmbando B, et al.
 Patterns and patient factors associated with loss to follow-up in the Muhimbili sickle
 cell cohort, Tanzania. BMC Health Serv Res. 2020 Dec 14;20(1):1141.
- 3. Makani J, Tluway F, Makubi A, Soka D, Nkya S, Sangeda R, et al. A ten year review of
 the sickle cell program in Muhimbili National Hospital, Tanzania. BMC Hematol.
 2018;18(1):1–13.
- Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer.
 2012 Aug;59(2):386–90.
- Staunton C, Moodley K. Challenges in biobank governance in Sub-Saharan Africa.
 BMC Med Ethics. 2013 Dec 11;14(1):35.

- Edwards T, Cadigan RJ, Evans JP, Henderson GE. Biobanks containing clinical
 specimens: Defining characteristics, policies, and practices. Clin Biochem. 2014
 Mar;47(4–5):245–51.
- 297 7. Hewitt RE. Biobanking: the foundation of personalized medicine. Curr Opin Oncol.
 298 2011 Jan;23(1):112–9.
- 8. Harati MD, Williams RR, Movassaghi M, Hojat A, Lucey GM, Yong WH. An
 Introduction to Starting a Biobank. In: Methods in Molecular Biology [Internet]. 2019.
- 301 p. 7–16. Available from: http://link.springer.com/10.1007/978-1-4939-8935-5 2
- 302 9. Siwek M. An Overview of Biorepositories—Past, Present, and Future. Mil Med. 2015
 303 Oct;180(10S):57–66.
- 304 10. Sirugo G, Loeff MS Van Der, Sam O, Nyan O, Pinder M, Hill A V, et al. A national
 305 DNA bank in The Gambia, West Africa, and genomic research in developing countries.
 306 Nat Genet. 2004 Aug;36(8):785–6.
- 307 11. Staunton C, Moodley K. Challenges in biobank governance in Sub-Saharan Africa.
 308 BMC Med Ethics. 2013 Dec 11;14(1):35.
- 309 12. Kelly SM, Wiehagen LT, Schumacher PE, Dhir R. Methods to Improve Sustainability
 310 of a Large Academic Biorepository. Biopreserv Biobank. 2017;15(1):31–6.
- 311 13. Doucet M, Yuille M, Georghiou L, Dagher G. Biobank sustainability: current status and
 future prospects. Journal of Biorepository Science for Applied Medicine. 2017;Volume
 5:1–7.
- Adedokun BO, Olopade CO, Olopade OI. Building local capacity for genomics research
 in Africa: Recommendations from analysis of publications in Sub-Saharan Africa from
 2004 to 2013. Glob Health Action. 2016;9(1):1–9.
- 317 15. De Souza YG, Greenspan JS. Biobanking past, present and future. AIDS. 2013
 318 Jan;27(3):303-12.

- 319 16. Harati MD, Williams RR, Movassaghi M, Hojat A, Lucey GM, Yong WH. An
- 320 Introduction to Starting a Biobank. In: Methods in Molecular Biology. 2019. p. 7–16.
- 321 17. Greenberg B, Christian J, Meltzer Henry L, Leavy M ichelle, Moore H. Biorepositories:
- 322 Addendum to Registries for Evaluating Patient Outcomes: A User's Guide,.
- 323 https://www.ncbi.nlm.nih.gov/books/NBK493632/#!po=12.5000; 2018.
- 18. Vaught JB, Henderson MK. Biological sample collection, processing, storage and
 information management. IARC Sci Publ. 2011;(163):23–42.
- 326 19. Oluwole OG, Oosterwyk C, Anderson D, Adadey SM, Mnika K, Manyisa N, et al. The
- 327 Implementation of Laboratory Information Management System in Multi-Site Genetics
- 328 Study in Africa: The Challenges and Up-Scaling Opportunities. Journal of Molecular
- 329 Pathology [Internet]. 2022;3(4):262–72. Available from: https://www.mdpi.com/2673330 5261/3/4/22
- 331 20. Makani J, Cox SE, Soka D, Komba AN, Oruo J, Mwamtemi H, et al. Mortality in Sickle
 332 Cell Anemia in Africa: A Prospective Cohort Study in Tanzania. Schrijver I, editor.
 333 PLoS One. 2011 Feb 16;6(2):e14699.
- Makani J, Komba AN, Cox SE, Oruo J, Mwamtemi K, Kitundu J, et al. Malaria in
 patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic
 and during hospitalization. Blood. 2010 Jan 14;115(2):215–20.
- 337 22. Mmbando BP, Mgaya J, Cox SE, Mtatiro SN, Soka D, Rwezaula S, et al. Negative
 338 epistasis between Sickle and foetal haemoglobin suggests a reduction in protection
 339 against malaria. PLoS One. 2015;10(5).
- 34023.Makani J, Mgaya J, Balandya E, Msami K, Soka D, Cox SE, et al. Bacteraemia in sickle

cell anaemia is associated with low haemoglobin: A report of 890 admissions to a

- 342 tertiary hospital in Tanzania. Br J Haematol. 2015;171(2):273–6.

341

- 343 24. Cox SE, Makani J, Fulford AJ, Komba AN, Soka D, Williams TN, et al. Nutritional
- 344 status, hospitalization and mortality among patients with sickle cell anemia in Tanzania. 345 Haematologica. 2011 Jul;96(7):948-53.
- 346 25. Makani J, Menzel S, Nkya S, Cox SE, Drasar E, Soka D, et al. Genetics of fetal 347 hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood, 2011 Jan 348 27;117(4):1390-2.
- 349 26. Makani J, Sangeda RZ, Nnodu O, Nembaware V, Osei-Akoto A, Paintsil V, et al. 350 SickleInAfrica. Lancet Haematol [Internet]. 2020 Feb;7(2):e98-9. Available from: 351 https://linkinghub.elsevier.com/retrieve/pii/S2352302620300065
- 352 27. Linsen L, Van Landuvt K, Ectors N. Automated Sample Storage in Biobanking to 353 Enhance Translational Research: The Bumpy Road to Implementation. Front Med 354 (Lausanne). 2020 Jan 9:6.
- Cox SE, Makani J, Ellins E, Walter G, Mtunguja S, Kirkham FJ, et al. Endothelial 355 28. 356 Function In Tanzanian Children With Sickle Cell Disease: Baseline Results From The 357 Vascular Function Intervention Trial (VFIT). Blood. 2013 Nov;122(21):984-984.
- 358 29. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap 359 consortium: Building an international community of software platform partners. J 360 Biomed Inform [Internet]. 2019 Jul:95:103208. Available from: 361 https://linkinghub.elsevier.com/retrieve/pii/S1532046419301261
- 362 30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for 363 364 providing translational research informatics support. J Biomed Inform [Internet]. 2009 365 Apr;42(2):377–81. Available from: 366

https://linkinghub.elsevier.com/retrieve/pii/S1532046408001226

367 31.	Cox SE, Makani J, Ellins E, Walter G, Mtunguja S, Kirkham FJ, et al. Endothelial
368	Function In Tanzanian Children With Sickle Cell Disease: Baseline Results From The
369	Vascular Function Intervention Trial (VFIT). Blood. 2013 Nov;122(21):984–984.
370 32.	Labarga A, Beloqui I, Martin AG. Information Management. In 2017. p. 29-39.
371	Available from: https://link.springer.com/10.1007/978-1-4939-6921-0_4
372 33.	Cicek MS, Olson JE. Mini-Review of Laboratory Operations in Biobanking: Building
373	Biobanking Resources for Translational Research. Front Public Health [Internet]. 2020
374	Jul 28;8. Available from:
375	https://www.frontiersin.org/article/10.3389/fpubh.2020.00362/full
376 34.	Vaught J, Lockhart NC. The evolution of biobanking best practices. Clinica Chimica
377	Acta [Internet]. 2012 Oct;413(19–20):1569–75. Available from:
378	https://linkinghub.elsevier.com/retrieve/pii/S0009898112002215
379	
380	

Figure captions

Fig 1: Freezers with the archived biospecimens. (A) -80C freezers for storing archived
biospecimen. (B) A picture showing the inside of one of the freezers. (C) Freezer plan map
showing cryobox positions within the freezer (Compartment, C-Column and R-Rack,
Biospecimen type: P-Plasma, FU-Follow-up, E-Entry, S-Serum)

386


Fig 2: Patients enrollment trend and biospecimen collection (A) Number of unique visiting
patients and biospecimens collected over the years 2004-2016 in Muhimbili Sickle Cohort
(MSC); (B) indicates the number of new patients enrolled each year.

- 391 Fig 3: Number of patients with a given number of biospecimens stored in the biorepository.
- 392 . The group labeled 1 is the group with patients with only one biospecimen collected and others
- are in intervals of 10 biospecimens.



	COLUMN	C1		C2		C3		C4		C5		C6	
OMPARTMENT	RACK	box labe	sample visits	box labe	sample	box label	sample visits	box labe	sample		sample	box labe	sample
	R1	P-B-77	CONTROL	P-C-1	all	P-C-25	all	P-4	CONTROL	P-9	FU	P-33	FU
		P-B-78	CONTROL	P-C-2	all	P-C-26	all	P-5	CONTROL	P-10	FU	P-34	FU
		P-B-79	CONTROL	P-C-3	all	P-C-27	all	P-6	CONTROL	P-11	FU	P-35	FU
		P-B-80	CONTROL	P-C-4	all	P-C-28	all	P/P-A-7	CONTROL	P-12	FU	P-36	FU
	R2	P-B-81	CONTROL	P-C-5	all	P-C-29	all	P-8	CONTROL	P-13	FU	P-37	FU
		P-B-82	CONTROL	P-C-6	all	P-C-30	all	P-A-9	CONTROL	P-14	FU	P-38	FU
		B-85	CONTROL	P-C-8	all	P-C-31	all	P-A-10	CONTROL	P-15	FU	P-39	FU
		B-86	CONTROL	HCV-9		P-C-32	all	P-A-11	CONTROL	P-16	FU	P-40	FU
	R3	B-81	CONTROL	P-C-9	all	P-C-33	all	P-A-12	CONTROL	P-17	FU	P-41	FU
		B-87	CONTROL	P-C-10	all	P-C-34	all	P-A-13	CONTROL	P-18	FU	P-42	FU
		B-88	CONTROL	P-C-11	all	P-C-35	all	P-A-14	CONTROL	P-19	FU	P-43	FU
		B-89	CONTROL	P-C-12	all	P-1	ADMISSION	P-A-15	CONTROL	P-20	FU	P-44	FU
	R4	P-B-40	ADMISSION	P-C-13	all	P-2	ADMISSION	P-A-16	CONTROL	P-21	FU	P-45	FU
		P-B-41	ADMISSION	P-C-14	all	P-3	ADMISSION	P-A-17	CONTROL	P-22	FU	P-46	FU
		P-B-43	ADMISSION	P-C-15	all	P-4	ADMISSION			P-23	FU	P-47	FU
		S-42	ADMISSION	P-C-16	all	P-5	ADMISSION			P-24	FU	P-48	FU
	R5	B-B-91	CONTROL	P-C-17	CONTROL	P-6	ADMISSION	P-1	FU	P-25	FU	P-49	FU
		P-B-257	FU+E		CONTROL	P-7	ADMISSION	P-2	FU	P-26	FU	P-50	FU
		S-43	ADMISSION		CONTROL	P-8	ADMISSION	P-3	FU	P-27	FU	P-51	FU
-		S-45	ADMISSION	P-C-20	CONTROL	P-1	CONTROL	P-4	FU	P-28	FU	P-52	FU
2	R6	P-B-258	FU+E		CONTROL	P-2	CONTROL	P-5	FU	P-29	FU	P-53	FU
õ					CONTROL	P-3	CONTROL	P-6	FU	P-30	FU	P-54	FU
0					CONTROL			P-7	FU	P-31	FU	P-55	FU
Uppel					CONTROL				FU	P-32	FU	P-56	FU
	R7	P-57	FU		FU	P-A-K	FU+E		FU	B-25	FU	B-45	FU
		P-58	FU		FU	P-A-L	FU+E	B-6	FU	B-26	FU	B-46	FU
		P-59	FU		FU	P-A-M	FU+E	-	FU	B-27	FU	B-47	FU
		P-60	FU		FU	P-A-N	FU+E	B-8	FU	B-28	FU	B-48	FU
	R8	P-61	FU		FU	P-A-0	FU+E	B-9	FU	B-29	FU	B-49	FU
		P/P-A-62	FU		FU	P-A-P	FU+E	B-10	FU	B-30	FU	B-50	FU
-		P-A-63	FU		FU	P-A-Q	FU+E	B-11	FU	B-31	FU	B-51	FU
-		P-A-64	FU		FU				FU	B-32	FU	B-52	FU
FREEZER	2 FREEZER 1		7 (+)	D 4 4	FULF	D. C. fas Analysis 7	All	D 40	FU	0.00	FU.	D 50	FU

Figure 1



• Total number of unique patients • Total number of samples

Figure 2




Figure 3